# GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

> **NCT05130255** · PHASE1 · RECRUITING · sponsor: **Y-mAbs Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- SCLC
- Malignant Melanoma
- Sarcoma
- High Risk Neuroblastoma

## Interventions

- **DRUG:** GD2-SADA:177Lu-DOTA Complex

## Key facts

- **NCT ID:** NCT05130255
- **Lead sponsor:** Y-mAbs Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-17
- **Primary completion:** 2027-03
- **Final completion:** 2027-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05130255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05130255, "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05130255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*